Abstract

BackgroundThe prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear.MethodFrom January 2009 to December 2015, a survival analysis was performed to retrospectively identify the prognostic value of SCLN metastasis on survival on 751 patients with EC treated with definitive chemo-radiotherapy (dCRT).ResultsThe median follow-up duration for living patients was 56.6 months. The median overall survival (OS) for all patients was 16.6 months. Patients with SCLN metastasis had a much poorer prognosis for OS (χ2 = 17.342, P < 0.001), distant metastasis-free survival (DMFS) (χ2 = 24.793, P < 0.001) and progression-free survival (PFS) (χ2 = 25.802, P < 0.001) than those without SCLN metastasis. The same results were found after propensity score matching. Nonetheless, the prognosis of patients with cervical or upper thoracic EC metastasis in SCLN was better than those of patients with middle or lower thoracic EC metastasis in SCLN for OS (χ2 = 4.516, P = 0.038), DMFS (χ2 = 8.326, P = 0.004) and PFS (χ2 = 6.255, P = 0.012). Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for PFS. Gender, age, middle or lower thoracic EC with SCLN metastasis, tumor diameter, tumor length, and number of lymph nodes were prognostic factors for DMFS. According to the multivariate analysis, only middle or lower thoracic EC with SCLN metastasis and number of lymph nodes were independent prognostic factors for DMFS and PFS.ConclusionFor patients with cervical or upper thoracic EC, metastasis in SCLN should be considered to be regional lymph nodes and treated with curative intent if the total number of lymph nodes is limited. However, for patients with middle or lower thoracic EC, metastasis should be considered to be a higher level N stage or M1 stage, and it is thus necessary to provide consolidation chemotherapy after dCRT.

Highlights

  • The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear

  • Esophageal cancer (EC) greatly threatens human health in China [1], and supra-clavicular lymph node (SCLN) metastasis accounts for approximately 8–20% of patients with EC, which have a much poorer prognosis [2,3,4,5,6,7,8]

  • Risk factors for survival Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for progression-free survival (PFS)

Read more

Summary

Introduction

The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear. Esophageal cancer (EC) greatly threatens human health in China [1], and supra-clavicular lymph node (SCLN) metastasis accounts for approximately 8–20% of patients with EC, which have a much poorer prognosis [2,3,4,5,6,7,8]. In the 7th edition of TNM staging, SCLN metastasis is defined as distant metastasis (M) and prognostically unfavorable [9]. In patients treated with dCRT, N stage disease is considered a prognostic factor [6,7,8]. The aim of the current study was to identify the prognostic value of SCLN for EC treated with dCRT

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.